Five Prime Therapeutics (FPRX) Tops Q1 EPS by 4c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q1 EPS of ($1.02), $0.04 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $5.35 million versus the consensus estimate of $4.79 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance